SALT LAKE CITY, March 12, 2025 /PRNewswire/ -- Lipocine Inc. (LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, ...
A decade ago, questions about the cardiovascular safety of testosterone replacement therapy prompted the US Food and Drug Administration (FDA) to require manufacturers to conduct new studies assessing ...
Members of an FDA expert panel urged the agency to expand labeling for testosterone replacement therapy and remove its classification as a controlled substance. Like previous FDA expert panels, the ...
Many healthcare providers regard testosterone cypionate and testosterone enanthate as interchangeable, but each has differences in their ingredients and duration of action. These differences influence ...
The FDA has announced new labeling changes for all testosterone products following a review of clinical trial data, including a TRAVERSE study and postmarket ambulatory blood pressure studies. The ...
Feb 28 (Reuters) - The U.S. Food and Drug Administration said on Friday it issued new labeling changes for testosterone products based on results from clinical and post-market studies testing the ...
Please provide your email address to receive an email when new articles are posted on . The FDA stated a warning about adverse CV outcomes with testosterone therapy can be removed based on data from ...
ON AN EARLY December morning in 2004, a panel of advisors to the Food & Drug Administration gathered at a hotel outside of Washington, D.C., to review some data. Pharmaceutical giant Procter & Gamble ...
This is T-rrific news for some men. Testosterone replacement therapy (TRT) has been historically difficult to get because it requires proof of consistently low testosterone levels along with symptoms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results